Unknown

Dataset Information

0

Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.


ABSTRACT: Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha and Beta variants. STI-2020 and STI-5041 were protective when administered intravenously or intranasally in the golden (Syrian) hamster model of COVID-19 challenged with the WA-1 strain or Beta variant. The ability to administer nAbs intravenously and intranasally may have important therapeutic implications and Phase 1 healthy subjects clinical trials are ongoing.

SUBMITTER: Cao X 

PROVIDER: S-EPMC9476467 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Unbiased approach to identify and assess efficacy of human SARS-CoV-2 neutralizing antibodies.

Cao Xia X   Maruyama Junki J   Zhou Heyue H   Fu Yanwen Y   Kerwin Lisa L   Powers Colin C   Sattler Rachel A RA   Manning John T JT   Singh Alok A   Lim Reyna R   Healy Laura D LD   Johnson Sachi S   Paz Cabral Elizabeth E   Li Donghui D   Lu Lucy L   Ledesma Arthur A   Lee Daniel D   Richards Susan S   Rivero-Nava Laura L   Li Yan Y   Shen Weiqun W   Stegman Karen K   Blair Benjamin B   Urata Shinji S   Kishimoto-Urata Magumi M   Ko Jamie J   Du Na N   Morais Kyndal K   Lawrence Kate K   Rivera Ianne I   Pai Chin-I CI   Bresson Damien D   Brunswick Mark M   Zhang Yanliang Y   Ji Henry H   Paessler Slobodan S   Allen Robert D RD  

Scientific reports 20220915 1


Coronavirus disease 2019 (COVID-19) continues to significantly impact the global population, thus countermeasure platforms that enable rapid development of therapeutics against variants of SARS-CoV-2 are essential. We report use of a phage display human antibody library approach to rapidly identify neutralizing antibodies (nAbs) against SARS-CoV-2. We demonstrate the binding and neutralization capability of two nAbs, STI-2020 and STI-5041, against the SARS-CoV-2 WA-1 strain as well as the Alpha  ...[more]

Similar Datasets

| S-BSST379 | biostudies-other
| EGAS00001004412 | EGA
| S-EPMC7584396 | biostudies-literature
| S-EPMC8755319 | biostudies-literature
| S-EPMC8251443 | biostudies-literature
| S-EPMC9059344 | biostudies-literature
| S-EPMC7506210 | biostudies-literature
| S-EPMC11619372 | biostudies-literature
| S-EPMC10983952 | biostudies-literature
| S-EPMC10388472 | biostudies-literature